AUPH Relative Valuation
AUPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AUPH is overvalued; if below, it's undervalued.
Historical Valuation
Aurinia Pharmaceuticals Inc (AUPH) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 2.87. The fair price of Aurinia Pharmaceuticals Inc (AUPH) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：15.31
Fair
18.90
PE
1Y
3Y
5Y
Trailing
Forward
10.77
EV/EBITDA
Aurinia Pharmaceuticals Inc. (AUPH) has a current EV/EBITDA of 10.77. The 5-year average EV/EBITDA is 2.52. The thresholds are as follows: Strongly Undervalued below -82.43, Undervalued between -82.43 and -39.95, Fairly Valued between 44.99 and -39.95, Overvalued between 44.99 and 87.46, and Strongly Overvalued above 87.46. The current Forward EV/EBITDA of 10.77 falls within the Historic Trend Line -Fairly Valued range.
12.62
EV/EBIT
Aurinia Pharmaceuticals Inc. (AUPH) has a current EV/EBIT of 12.62. The 5-year average EV/EBIT is -39.76. The thresholds are as follows: Strongly Undervalued below -377.08, Undervalued between -377.08 and -208.42, Fairly Valued between 128.90 and -208.42, Overvalued between 128.90 and 297.55, and Strongly Overvalued above 297.55. The current Forward EV/EBIT of 12.62 falls within the Historic Trend Line -Fairly Valued range.
6.40
PS
Aurinia Pharmaceuticals Inc. (AUPH) has a current PS of 6.40. The 5-year average PS is 10.23. The thresholds are as follows: Strongly Undervalued below -8.22, Undervalued between -8.22 and 1.01, Fairly Valued between 19.46 and 1.01, Overvalued between 19.46 and 28.69, and Strongly Overvalued above 28.69. The current Forward PS of 6.40 falls within the Historic Trend Line -Fairly Valued range.
11.52
P/OCF
Aurinia Pharmaceuticals Inc. (AUPH) has a current P/OCF of 11.52. The 5-year average P/OCF is -5.42. The thresholds are as follows: Strongly Undervalued below -58.84, Undervalued between -58.84 and -32.13, Fairly Valued between 21.30 and -32.13, Overvalued between 21.30 and 48.01, and Strongly Overvalued above 48.01. The current Forward P/OCF of 11.52 falls within the Historic Trend Line -Fairly Valued range.
16.42
P/FCF
Aurinia Pharmaceuticals Inc. (AUPH) has a current P/FCF of 16.42. The 5-year average P/FCF is -2.31. The thresholds are as follows: Strongly Undervalued below -124.33, Undervalued between -124.33 and -63.32, Fairly Valued between 58.69 and -63.32, Overvalued between 58.69 and 119.70, and Strongly Overvalued above 119.70. The current Forward P/FCF of 16.42 falls within the Historic Trend Line -Fairly Valued range.
Aurinia Pharmaceuticals Inc (AUPH) has a current Price-to-Book (P/B) ratio of 5.52. Compared to its 3-year average P/B ratio of 3.17 , the current P/B ratio is approximately 73.83% higher. Relative to its 5-year average P/B ratio of 3.88, the current P/B ratio is about 42.33% higher. Aurinia Pharmaceuticals Inc (AUPH) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -0.71%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -3.56% , the current FCF yield is about -100.00% lower.
5.52
P/B
Median3y
3.17
Median5y
3.88
6.09
FCF Yield
Median3y
-0.71
Median5y
-3.56
Competitors Valuation Multiple
The average P/S ratio for AUPH's competitors is , providing a benchmark for relative valuation. Aurinia Pharmaceuticals Inc Corp (AUPH) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 8.41%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AUPH increased by 70.49% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 21.17 to 42.95.
The secondary factor is the Revenue Growth, contributed 8.41%to the performance.
Overall, the performance of AUPH in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Aurinia Pharmaceuticals Inc (AUPH) currently overvalued or undervalued?
What is Aurinia Pharmaceuticals Inc (AUPH) fair value?
How does AUPH's valuation metrics compare to the industry average?
What is the current P/B ratio for Aurinia Pharmaceuticals Inc (AUPH) as of Dec 05 2025?
What is the current FCF Yield for Aurinia Pharmaceuticals Inc (AUPH) as of Dec 05 2025?
What is the current Forward P/E ratio for Aurinia Pharmaceuticals Inc (AUPH) as of Dec 05 2025?